{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T21:01:26Z","timestamp":1776978086958,"version":"3.51.4"},"reference-count":40,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      Israel has pioneered population-wide screening (PS) for\n                      <jats:italic toggle=\"yes\">BRCA<\/jats:italic>\n                      pathogenic variants (PVs). We aimed to compare psychosocial aspects and outcomes of carriers identified through PS versus via oncogenetic clinics (OC) in a real-world setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      A cohort study conducted at\n                      <jats:italic toggle=\"yes\">BRCA<\/jats:italic>\n                      high-risk surveillance clinic in Shaare Zedek Medical Center Jerusalem, Israel (9.2021-5.2024). Data were obtained from electronic medical records and self-reported questionnaires. The study included newly identified unaffected female\n                      <jats:italic toggle=\"yes\">BRCA1\/2<\/jats:italic>\n                      PV carriers: PS carriers received only post-test genetic counseling, whereas OC carriers received both pre- and post-test counseling.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      We identified 352 carriers: 202 PS and 150 OC. Sociodemographic characteristics were similar. PS carriers harbored more\n                      <jats:italic toggle=\"yes\">BRCA2<\/jats:italic>\n                      -PVs (62.9%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      48.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .001) rather than\n                      <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>\n                      -PVs, and fewer had suggestive family history (FH) (40.4%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      61%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). In univariate analysis, both groups reported satisfaction with pretest information. PS carriers reported lower satisfaction with result delivery: (3.3 \u00b1 1.3\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      3.9 \u00b1 1.2 [scale 1-5];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .001) and health decisions: (24.6 \u00b1 3.9\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      25.9 \u00b1 3.6 [scale 6-30];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .014). However, testing mode was not predictive of psychosocial outcomes in multivariate analysis. Risk-reducing bilateral salpingo-oophorectomy (RR-BSO) rates at recommended age were similar in PS and OC:\n                      <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>\n                      \u226540 years: 74.1% versus 85.7%,\n                      <jats:italic toggle=\"yes\">BRCA2<\/jats:italic>\n                      \u226545 years: 81.4% versus 63.5%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      In a real-world setting, PS identified carriers with less FH and more\n                      <jats:italic toggle=\"yes\">BRCA2<\/jats:italic>\n                      -PVs. PS was associated with favorable psychosocial outcomes and high RR-BSO uptake. The process requires refinement and long-term evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-25-01023","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T19:59:11Z","timestamp":1776974351000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Analysis of\n                    <i>BRCA<\/i>\n                    Pathogenic Variant Detection in a Real-World Setting: Population Screening Versus Oncogenetic Clinics"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0216-9948","authenticated-orcid":true,"given":"Shunit","family":"Armon","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel"},{"name":"The Eisenberg R&amp;D Authority, Shaare Zedek Medical Center, Jerusalem, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1671-6444","authenticated-orcid":true,"given":"Sari","family":"Lieberman","sequence":"additional","affiliation":[{"name":"The Eisenberg R&amp;D Authority, Shaare Zedek Medical Center, Jerusalem, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel"},{"name":"The Fuld Family Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Michaelson-Cohen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel"},{"name":"The Eisenberg R&amp;D Authority, Shaare Zedek Medical Center, Jerusalem, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel"},{"name":"The Fuld Family Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariela","family":"Tomer","sequence":"additional","affiliation":[{"name":"The Eisenberg R&amp;D Authority, Shaare Zedek Medical Center, Jerusalem, Israel"},{"name":"The Fuld Family Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einat","family":"Koller-Volkow","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2637-1921","authenticated-orcid":true,"given":"Ephrat","family":"Levy-Lahad","sequence":"additional","affiliation":[{"name":"The Eisenberg R&amp;D Authority, Shaare Zedek Medical Center, Jerusalem, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel"},{"name":"The Fuld Family Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naama","family":"Srebnik","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel"},{"name":"The Eisenberg R&amp;D Authority, Shaare Zedek Medical Center, Jerusalem, Israel"},{"name":"Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7112"},{"key":"e_1_3_7_3_2","unstructured":"Dwyer M: NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae) genetic\/familial high-risk assessment: Breast ovarian pancreatic and prostate. 2025. https:\/\/www.nccn.org"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.6937"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05345-2"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.6944"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2014.147"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1415979111"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1088759"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.182"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.175"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju379"},{"key":"e_1_3_7_13_2","unstructured":"Reference deleted"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e31815699d0"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246113"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju380"},{"key":"e_1_3_7_17_2","volume-title":"Ministry of Health Medical Technologies Supplement a 2020: 2020","unstructured":"Ministry of Health Medical Technologies Supplement a 2020: 2020. https:\/\/www.gov.il\/BlobFolder\/policy\/mk03-2020\/he\/files_circulars_mk_mk03_2020.pdf"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.514"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-006-9261-5"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2010.01499.x"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9601600114"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.4.442"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1992.tb00997.x"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/08964289.1990.9934587"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19990101)82:1<53::AID-AJMG11>3.0.CO;2-#"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3182217a19"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2024-110390"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0712"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.004"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2023.100824"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.244"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1941-0"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0861-3"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9557"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-20-0002"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0446-1"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05949-z"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01334"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2059"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-01023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T19:59:17Z","timestamp":1776974357000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-01023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1200\/PO-25-01023"],"URL":"https:\/\/doi.org\/10.1200\/po-25-01023","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2501023"}}